top of page
A spin off from the Hospital Clinic Barcelona (Spain) founded in May 2020 and supported by a 1.5m € seed investment from
Gyala Therapeutics is developing a CAR T cell product against a novel target overexpressed in several hematological malignancies.
Hospital Clinic and IDIBAPS have significant experience and know-how on preclinical and clinical development of CAR T cell products and in the treatment of haematological malignancies.
The scientists and clinicians involved in Gyala have developed ARI-0001, a CART targeting CD19 that has been approved by the Spanish regulatory agency, and ARI-0002, a CART targeting BCMA currently in clinical development.
bottom of page